Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -223.6%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $4M | $3M | $76M | $728M | $1.0B | $1.3B | $2.2B | $3.0B | $2.4B | $2.1B |
| Enterprise Value | $1M | $4M | $8M | $85M | $730M | $1.0B | $1.3B | $2.2B | $3.0B | $2.4B | $2.1B |
| P/E Ratio → | -0.05 | — | — | — | — | — | — | — | — | — | 38394.50 |
| P/S Ratio | — | — | 2.29 | 60.79 | 605.27 | 750.85 | 969.50 | 1406.34 | 1901.17 | 2263.24 | 3471.82 |
| P/B Ratio | 0.10 | 0.42 | 0.43 | 10.36 | 65.21 | 338.61 | 324.45 | 487.03 | 263.92 | 333.67 | 603.52 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 156790.24 |
| P/OCF | — | — | — | — | — | — | — | — | — | — | 153045.40 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 6.03 | 67.44 | 607.41 | 752.64 | 971.68 | 1407.91 | 1900.37 | 2261.82 | 3467.13 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | 27771.94 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | 27575.23 |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | 156578.80 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 20.1% | 19.0% | 22.7% | 29.8% | 28.3% | 22.0% | 24.8% | 23.0% | 88.1% |
| Operating Margin | — | — | -369.6% | -1254.6% | -731.4% | -635.1% | -903.9% | -1253.1% | -488.5% | -359.9% | 12.5% |
| Net Profit Margin | — | — | -592.7% | -1330.5% | -992.4% | -653.5% | -920.3% | -1168.6% | -497.6% | -321.5% | 9.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -223.6% | -223.6% | -109.2% | -180.3% | -167.5% | -252.5% | -295.5% | -229.9% | -83.8% | -63.8% | 3.1% |
| ROA | -82.3% | -82.3% | -38.0% | -82.8% | -79.6% | -88.2% | -121.6% | -151.3% | -59.7% | -42.3% | 3.0% |
| ROIC | -53.7% | -53.7% | -26.6% | -80.2% | -68.3% | -104.4% | -133.3% | -172.1% | -72.5% | -90.3% | 17.5% |
| ROCE | -92.8% | -92.8% | -47.1% | -105.1% | -79.9% | -129.8% | -161.4% | -194.7% | -78.0% | -71.4% | 4.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 1.10 | 1.17 | 0.41 | 1.07 | 0.91 | 0.71 | 0.09 | 0.21 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | 0.70 | 1.13 | 0.23 | 0.81 | 0.73 | 0.54 | -0.11 | -0.21 | -0.81 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | -37.50 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -211.44 |
| Interest Coverage | -11.03 | -11.03 | -2.24 | -11.36 | -2.34 | -44.34 | -74.13 | -29.57 | -24.42 | -28.32 | — |
Net cash position: cash ($109091) exceeds total debt ($6000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.11 | 0.11 | 0.23 | 0.13 | 0.66 | 0.26 | 0.50 | 0.55 | 3.18 | 0.60 | 23.12 |
| Quick Ratio | 0.11 | 0.11 | 0.23 | 0.13 | 0.66 | 0.26 | 0.31 | 0.38 | 3.16 | 0.60 | 18.75 |
| Cash Ratio | 0.01 | 0.01 | 0.21 | 0.04 | 0.56 | 0.18 | 0.28 | 0.27 | 1.97 | 0.56 | 18.00 |
| Asset Turnover | — | — | 0.06 | 0.06 | 0.06 | 0.14 | 0.13 | 0.15 | 0.12 | 0.09 | 0.17 |
| Inventory Turnover | — | — | 11.55 | — | — | — | 2.00 | 2.39 | 90.37 | 311.13 | 0.10 |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | 0.0% |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | 0.0% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $3M | $936614 | $11M | $9M | $8M | $8M | $8M | $7M | $7M | $5M |
Imminent liquidity exhaustion
Based on reported figures, ALBT trades at a price-to-book ratio of 0.10, which suggests that the market assigns minimal value to the company's intangible assets and intellectual property portfolio, likely due to the extreme uncertainty surrounding its transition from legacy real estate services to speculative biotechnology R&D.
The current valuation multiples appear to reflect a deep discount, as the market struggles to price a firm with no revenue and a precarious cash position. Investors should monitor whether this low P/B ratio indicates a genuine undervaluation of the QTY-code technology or a rational market expectation of further shareholder dilution.
As reported in financial statements, the company's ROIC has remained consistently negative, reaching -18.2% in 2026Q1, which demonstrates that the firm is currently unable to generate any productive return on the capital deployed into its clinical-stage research and development initiatives.
The persistent negative trend in ROIC suggests that management's capital allocation has failed to create value, as resources are consumed by overhead rather than clinical milestones. This decay in returns warrants further investigation into whether the current R&D pipeline can ever achieve the scale necessary to reach profitability.
According to recent SEC filings, the company's current ratio of 0.38 in 2026Q1 highlights a severe liquidity deficit, indicating that the firm lacks the necessary short-term assets to cover its immediate operational obligations without securing additional external financing or dilutive capital injections.
The quick ratio of 0.36 confirms that the company is almost entirely dependent on its dwindling cash reserves to sustain its current burn rate. This position appears highly vulnerable, as any delay in clinical progress or funding could lead to a critical failure in meeting basic operational requirements.
As indicated by the company's historical data, the use of P/E or EV/EBITDA ratios is fundamentally misapplied to ALBT, as these metrics obscure the reality that the firm is a pre-revenue biotech incubator rather than a functioning real estate services entity with predictable earnings.
Analysts should instead focus on cash runway and clinical milestone progress, as traditional valuation multiples are rendered meaningless by the absence of operating income. Relying on historical sector-based metrics may lead to a dangerous underestimation of the company's actual financial risk and its reliance on external funding.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALBT stock.
Avalon GloboCare Corp.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Avalon GloboCare Corp.'s return on equity (ROE) is -223.6%. The historical average is -160.3%.
Based on historical data, Avalon GloboCare Corp. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.